Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23249299 | 0.81 | DRD2 (0.32) | HTR1A | |
| SCHEMBL23249573 | 0.77 | HTR1A (0.39) | SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL23261646 | 0.77 | DRD2 (0.36) | SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL23249326 | 0.70 | HTR1A (0.54) | SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL23248791 | 0.70 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL23248800 | 0.65 | HTR1A (0.33) | HTR1A | |
| SCHEMBL23249335 | 0.61 | DRD2 (0.42) | HTR1A | |
| SCHEMBL23249586 | 0.58 | HTR1A (0.39) | HTR1A | |
| SCHEMBL23249531 | 0.57 | HTR1A (0.54) | HTR1A | |
| SCHEMBL11348398 | 0.55 | HTR2A (0.41) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295106-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | DELIX THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295106-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | DELIX THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295106-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | DELIX THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2021076572-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021076572-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295106-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | GRIN1, GRIN2A, GRIN3B | SLC6A2 133/4885SLC6A4 237/4885SLC6A3 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.